Evidence map›Paper›PMID 38217544›Full record

ArticleAging2024

LAMP3 is a potent uterine corpus endometrial carcinoma prognostic biomarker associated with immune behavior.

Bidong Fu, Minqin Zhou, Xitong Geng, Yike Jiang, Hong Zeng, Xuanrui Zhou, Zichuan Yu, Jingying Pan, Yanting Zhu, Hao Zheng and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Bidong FuDepartment of Obstetrics and Gynecology, Second Affiliated Hospital of Nanchang University, Nanchang, China.
Minqin ZhouSecond College of Clinical Medicine, Nanchang University, Nanchang, China.
Xitong GengSecond College of Clinical Medicine, Nanchang University, Nanchang, China.
Yike JiangSecond College of Clinical Medicine, Nanchang University, Nanchang, China.
Hong ZengSecond College of Clinical Medicine, Nanchang University, Nanchang, China.
Xuanrui ZhouSecond College of Clinical Medicine, Nanchang University, Nanchang, China.
Zichuan YuSecond College of Clinical Medicine, Nanchang University, Nanchang, China.
Jingying PanSecond College of Clinical Medicine, Nanchang University, Nanchang, China.
Yanting ZhuSecond College of Clinical Medicine, Nanchang University, Nanchang, China.
Hao ZhengSecond College of Clinical Medicine, Nanchang University, Nanchang, China.
Shuhan HuangSecond College of Clinical Medicine, Nanchang University, Nanchang, China.
Yiyang GongSecond College of Clinical Medicine, Nanchang University, Nanchang, China.
Da HuangDepartment of Thyroid Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, China.
Yanying ZhongDepartment of Obstetrics and Gynecology, Second Affiliated Hospital of Nanchang University, Nanchang, China.
Nanchang University · CNSecond Affiliated Hospital of Nanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUterine corpus endometrial carcinoma (UCEC) is one of the most common gynecological malignancies and its incidence and mortality continue apace. Lysosome-associated membrane protein 3 (LAMP3) is the third member of the LAMP family and its overexpression has been described to be involved in the progression of breast, ovarian and cervical cancers, but there has been an absence of research focusing on its role in UCEC.

methodsWGCNA, TIMER, LinkedOmics, GSEA, Cytoscape, Kaplan-Meier plotter, GDC, GeneMANIA, cBioPortal, PDB, RNAinter, miRNet were applied in this research.

resultsOur study uncovers that LAMP3 possesses higher expression levels in UCEC compared to normal tissues, and this differential expression profile is tightly aligned with clinical and pathological features, and patients demonstrating high LAMP3 expression tend to have a shorter survival expectancy. The high expression of LAMP3 is modulated by the designated ceRNA network. LAMP3 is engaged in UCEC progression by functioning in a variety of biological roles of relevance to immunity. Furthermore, we predicted several prospering drugs based on drug sensitivity. Finally, we also constructed possible docking patterns of LAMP3 with ABCA3, RAB9A, and SGTB.

conclusionsLAMP3 is a formidable biomarker for UCEC and could be a prospective candidate for the diagnosis, treatment and prognostic assessment of UCEC.

Indexed as

BreastCarcinoma, EndometrioidFemaleHumansLysosomal-Associated Membrane Protein 3Neoplasm ProteinsPrognosisLAMP3 protein, humanLysosomal-Associated Membrane Protein 3Neoplasm Proteinsimmune infiltrationLAMP3prognosisuterine corpus endometrial carcinomaWGCNA

Identifiers

PMID38217544
PMCPMC10817406
OpenAlexW4390765483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.